- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Celltrion Inc (068270)
Track today's live Celltrion (068270) share price, performance and key data on this page with our current Seoul:068270 stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Celltrion share price on the Seoul exchange. Use the dropdown to switch exchange for the 068270 share price, head to our technical summary section, which provides analysis on Celltrion share price buy/sell indicators using real-time data (or discuss the Celltrion (068270) stock price today with other investors in the Celltrion KS share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current KS:068270 share price (ISIN: KR7068270008) to enhance your trading decisions with our free investment tools and resources.
What Is the Celltrion Inc Share Price Today?
The Celltrion share price today is 180,400.
What Is the Stock Symbol for Celltrion Inc
The stock symbol (or 'ticker') for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current KS:068270 share price (ISIN: KR7068270008) to enhance your trading decisions with our free investment tools and resources.
What Is the Celltrion Inc Share Price Today?
The Celltrion share price today is 180,400.
What Is the Stock Symbol for Celltrion Inc
The stock symbol (or 'ticker') for Celltrion Inc is "068270."
What Stock Exchange Does Celltrion Inc Trade On?
Celltrion Inc is listed and trades on the Seoul stock exchange.
Is Celltrion Inc a Good Stock to Buy?
Determining whether Celltrion (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
180,400
+800(+0.45%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
179,800
184,400
52 wk Range
158,500
239,048
068270 is included in our AI-picked strategies. See how they work
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
179,800184,400
52 wk Range
158,500239,048
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.40%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.40%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
068270 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
267,741
Upside
+48.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Has raised its dividend for 3 consecutive years
Celltrion Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Celltrion Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Celltrion Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Celltrion Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Celltrion Inc receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
20 Buy
2 Hold
0 Sell
Ratings:
22 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 267,741
(+48.42% Upside)
Earnings
Latest Release
14/08/2026
EPS / Forecast
1,591.89 / 1,450.51
Revenue / Forecast
1.39T / 1.31T
Compare 068270 to Peers and Sector
Metrics to compare | 068270 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship068270PeersSector | |
|---|---|---|---|---|
P/E Ratio | 26.1x | 27.8x | −0.3x | |
PEG Ratio | 0.12 | 0.09 | 0.00 | |
Price/Book | 2.3x | 1.8x | 2.6x | |
Price / LTM Sales | 8.4x | 3.3x | 3.0x | |
Upside (Analyst Target) | 48.4% | 49.1% | 59.8% | |
Fair Value Upside | Unlock | 23.7% | 7.1% | Unlock |
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Celltrion (Seoul: 068270) Share Price Today?
The Celltrion stock price today is 180,400 KRW.
What Stock Exchange Does Celltrion (068270) Trade On?
Celltrion is listed and trades on the Seoul Stock Exchange.
What Is the Ticker (Stock Symbol) for Celltrion?
The stock symbol (also called a 'ticker') for Celltrion is "068270."
Does Celltrion Pay Dividends? What’s The Current 068270 Dividend Yield?
Yes, 068270 Pays Dividends to its Shareholders. The current Celltrion dividend yield is 0.4%.
What Is the Current Celltrion Market Capitalisation?
As of today, Celltrion (Seoul: 068270) market cap is 41.03T KRW.
What Is Celltrion's (068270) Earnings Per Share (TTM)?
The Celltrion EPS is currently 6,840 (Trailing Twelve Months).
When Is the Next Celltrion Earnings Date?
Celltrion's next earnings report will be released on 05/11/2026.
Is 068270 a Buy or Sell From a Technical Analyst Perspective?
Based on today's Celltrion moving averages and other technical indicators, the daily buy/sell signal for 068270 stock is Sell.
How Many Times Has Celltrion Stock Split?
Celltrion has split 19 times. (See the 068270 stock split history page for full effective split date and price information.)
How Many Employees Does Celltrion Have?
Celltrion has 2956 employees, based on their latest Companies House report.
What is the current trading status of Celltrion (Seoul: 068270)?
As of 12/10/2026, Celltrion (068270) is trading at a share price of 180,400 KRW, with a previous close of 179,600 KRW. The stock has fluctuated within a day range of 179,800 KRW to 184,400 KRW, while its 52-week range spans from 158,500 KRW to 239,048 KRW.
What Is Celltrion (068270) Price Target According to Analysts?
The average 12-month price target for Celltrion is 267,741 KRW, with a high estimate of 310000 KRW and a low estimate of 200000 KRW. 20 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +48.42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.